$CNXU News

Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

Conexeu Sciences shares are trading higher after the company announced it advanced Ten Minute Tissue towards a planned FDA 510(k) submission.

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

Conexeu Sciences Issues Update On Regulatory And Manufacturing Program Supporting Planned FDA 510(k) Premarket Notification For Ten Minute Tissue, Lead Wound Care Device Candidate

Conexeu Sciences Sets September and October 2026 Conference Schedule

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

HC Wainwright & Co. Initiates Coverage On Conexeu Sciences with Buy Rating, Announces Price Target of $20

Is Conexeu Sciences (CNXU) Quietly Redefining Its Commercial Ambitions With CXU Platform Moves?

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"